-
1
-
-
0031760564
-
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII
-
Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S61-5.
-
(1998)
Blood Coagul Fibrinolysis
, vol.9
, Issue.Suppl. 1
-
-
Hoffman, M.1
Monroe, D.M.2
Roberts, H.R.3
-
2
-
-
0033767885
-
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders
-
van't Veer C, Mann KG. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders. Semin Thromb Hemost 2000; 26: 367-72.
-
(2000)
Semin Thromb Hemost
, vol.26
, pp. 367-372
-
-
van't Veer, C.1
Mann, K.G.2
-
3
-
-
33846185403
-
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
-
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, Group FS. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
-
(2007)
Blood
, vol.109
, pp. 546-551
-
-
Astermark, J.1
Donfield, S.M.2
DiMichele, D.M.3
Gringeri, A.4
Gilbert, S.A.5
Waters, J.6
Berntorp, E.7
Group, F.S.8
-
4
-
-
44649185547
-
Arthropathy in inhibitor patients: differences in the joint status
-
Hoots WK. Arthropathy in inhibitor patients: differences in the joint status. Semin Hematol 2008; 45: S42-9.
-
(2008)
Semin Hematol
, vol.45
-
-
Hoots, W.K.1
-
5
-
-
84855374941
-
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
-
1804 (adept(TM)1) Investigators.s
-
de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A, 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012; 10: 81-9.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 81-89
-
-
de Paula, E.V.1
Kavakli, K.2
Mahlangu, J.3
Ayob, Y.4
Lentz, S.R.5
Morfini, M.6
Nemes, L.7
Šalek, S.Z.8
Shima, M.9
Windyga, J.10
Ehrenforth, S.11
Chuansumrit, A.12
-
6
-
-
59049098711
-
Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects
-
Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009; 7: 299-305.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 299-305
-
-
Møss, J.1
Scharling, B.2
Ezban, M.3
Møller Sørensen, T.4
-
7
-
-
84855832171
-
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
-
Milanov P, Ivanciu L, Abriss D, Quade-Lyssy P, Miesbach W, Alesci S, Tonn T, Grez M, Seifried E, Schüttrumpf J. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 2012; 119: 602-11.
-
(2012)
Blood
, vol.119
, pp. 602-611
-
-
Milanov, P.1
Ivanciu, L.2
Abriss, D.3
Quade-Lyssy, P.4
Miesbach, W.5
Alesci, S.6
Tonn, T.7
Grez, M.8
Seifried, E.9
Schüttrumpf, J.10
-
8
-
-
80755125572
-
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
-
Ivanciu L, Toso R, Margaritis P, Pavani G, Kim H, Schlachterman A, Liu JH, Clerin V, Pittman DD, Rose-Miranda R, Shields KM, Erbe DV, Tobin JF, Arruda VR, Camire RM. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol 2011; 29: 1028-33.
-
(2011)
Nat Biotechnol
, vol.29
, pp. 1028-1033
-
-
Ivanciu, L.1
Toso, R.2
Margaritis, P.3
Pavani, G.4
Kim, H.5
Schlachterman, A.6
Liu, J.H.7
Clerin, V.8
Pittman, D.D.9
Rose-Miranda, R.10
Shields, K.M.11
Erbe, D.V.12
Tobin, J.F.13
Arruda, V.R.14
Camire, R.M.15
-
9
-
-
49649122047
-
The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly
-
Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J Biol Chem 2008; 283: 18627-35.
-
(2008)
J Biol Chem
, vol.283
, pp. 18627-18635
-
-
Toso, R.1
Zhu, H.2
Camire, R.M.3
-
10
-
-
0023924910
-
Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
-
Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-56.
-
(1988)
Annu Rev Biochem
, vol.57
, pp. 915-956
-
-
Mann, K.G.1
Jenny, R.J.2
Krishnaswamy, S.3
-
11
-
-
0018622772
-
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase
-
Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-62.
-
(1979)
J Biol Chem
, vol.254
, pp. 10952-10962
-
-
Nesheim, M.E.1
Taswell, J.B.2
Mann, K.G.3
-
12
-
-
0036707993
-
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
-
Gale AJ, Xu X, Pellequer JL, Getzoff ED, Griffin JH. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 2002; 11: 2091-101.
-
(2002)
Protein Sci
, vol.11
, pp. 2091-2101
-
-
Gale, A.J.1
Xu, X.2
Pellequer, J.L.3
Getzoff, E.D.4
Griffin, J.H.5
-
13
-
-
23944516887
-
Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?
-
Bos MH, Meijerman DW, van der Zwaan C, Mertens K. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? J Thromb Haemost 2005; 3: 522-30.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 522-530
-
-
Bos, M.H.1
Meijerman, D.W.2
van der Zwaan, C.3
Mertens, K.4
-
14
-
-
0345627213
-
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN)
-
van't Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997; 90: 3067-72.
-
(1997)
Blood
, vol.90
, pp. 3067-3072
-
-
van't Veer, C.1
Golden, N.J.2
Kalafatis, M.3
Simioni, P.4
Bertina, R.M.5
Mann, K.G.6
-
15
-
-
29244443415
-
Factor V Leiden improves in vivo hemostasis in murine hemophilia models
-
Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, Poncz M, Camire RM, Arruda VR. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 2005; 3: 2730-7.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 2730-2737
-
-
Schlachterman, A.1
Schuettrumpf, J.2
Liu, J.H.3
Furlan Freguia, C.4
Toso, R.5
Poncz, M.6
Camire, R.M.7
Arruda, V.R.8
-
16
-
-
76449092195
-
Factor V Leiden and hemophilia
-
Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010; 125: 119-23.
-
(2010)
Thromb Res
, vol.125
, pp. 119-123
-
-
Franchini, M.1
Lippi, G.2
-
17
-
-
0026321606
-
Identification of a sequence of human activated protein-C (residues 390-404). Essential for its anticoagulant activity
-
Mesters R, Houghten R, Griffin J. Identification of a sequence of human activated protein-C (residues 390-404). Essential for its anticoagulant activity. J Biol Chem 1991; 266: 24514-9.
-
(1991)
J Biol Chem
, vol.266
, pp. 24514-24519
-
-
Mesters, R.1
Houghten, R.2
Griffin, J.3
-
18
-
-
85027928249
-
Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va
-
Cramer TJ, Griffin JH, Gale AJ. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 2010; 37: 17-23.
-
(2010)
Pathophysiol Haemost Thromb
, vol.37
, pp. 17-23
-
-
Cramer, T.J.1
Griffin, J.H.2
Gale, A.J.3
-
19
-
-
2442655492
-
Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized
-
Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem 2004; 279: 21643-50.
-
(2004)
J Biol Chem
, vol.279
, pp. 21643-21650
-
-
Toso, R.1
Camire, R.M.2
-
20
-
-
36349014743
-
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions
-
Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022-33.
-
(2007)
J Biol Chem
, vol.282
, pp. 33022-33033
-
-
Mosnier, L.O.1
Yang, X.V.2
Griffin, J.H.3
-
21
-
-
0142072235
-
The Calibrated Automated Thrombogram (CAT): A universal routine test for hyper- and hypocoagulability
-
Hemker H, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The Calibrated Automated Thrombogram (CAT): A universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
-
(2002)
Pathophysiol Haemost Thromb
, vol.32
, pp. 249-253
-
-
Hemker, H.1
Giesen, P.2
AlDieri, R.3
Regnault, V.4
de Smed, E.5
Wagenvoord, R.6
Lecompte, T.7
Beguin, S.8
-
22
-
-
84875530235
-
Antibody SPC-54 provides acute in vivo blockage of the murine protein C system
-
Burnier L, Fernández JA, Griffin JH. Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells Mol Dis 2013; 50: 252-8.
-
(2013)
Blood Cells Mol Dis
, vol.50
, pp. 252-258
-
-
Burnier, L.1
Fernández, J.A.2
Griffin, J.H.3
-
23
-
-
77955492929
-
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
-
Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
-
(2010)
Blood
, vol.116
, pp. 270-279
-
-
Mei, B.1
Pan, C.2
Jiang, H.3
Tjandra, H.4
Strauss, J.5
Chen, Y.6
Liu, T.7
Zhang, X.8
Severs, J.9
Newgren, J.10
Chen, J.11
Gu, J.M.12
Subramanyam, B.13
Fournel, M.A.14
Pierce, G.F.15
Murphy, J.E.16
-
24
-
-
2342666603
-
An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa
-
Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003; 1: 1966-71.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 1966-1971
-
-
Gale, A.J.1
Pellequer, J.L.2
-
25
-
-
33646765242
-
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
-
Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4: 1315-22.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 1315-1322
-
-
Gale, A.J.1
Radtke, K.P.2
Cunningham, M.A.3
Chamberlain, D.4
Pellequer, J.L.5
Griffin, J.H.6
-
26
-
-
0018786088
-
The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity
-
Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979; 254: 964-73.
-
(1979)
J Biol Chem
, vol.254
, pp. 964-973
-
-
Esmon, C.T.1
-
27
-
-
22544469092
-
Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase
-
Bianchini EP, Orcutt SJ, Panizzi P, Bock PE, Krishnaswamy S. Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase. Proc Natl Acad Sci U S A 2005; 102: 10099-104.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 10099-10104
-
-
Bianchini, E.P.1
Orcutt, S.J.2
Panizzi, P.3
Bock, P.E.4
Krishnaswamy, S.5
-
28
-
-
36349000220
-
Further evidence for two functional forms of prothrombinase each specific for either of the two prothrombin activation cleavages
-
Kim PY, Nesheim ME. Further evidence for two functional forms of prothrombinase each specific for either of the two prothrombin activation cleavages. J Biol Chem 2007; 282: 32568-81.
-
(2007)
J Biol Chem
, vol.282
, pp. 32568-32581
-
-
Kim, P.Y.1
Nesheim, M.E.2
-
29
-
-
84887052679
-
Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis
-
Lechtenberg BC, Murray-Rust TA, Johnson DJ, Adams TE, Krishnaswamy S, Camire RM, Huntington JA. Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Blood 2013; 122: 2777-83.
-
(2013)
Blood
, vol.122
, pp. 2777-2783
-
-
Lechtenberg, B.C.1
Murray-Rust, T.A.2
Johnson, D.J.3
Adams, T.E.4
Krishnaswamy, S.5
Camire, R.M.6
Huntington, J.A.7
-
30
-
-
0030792746
-
Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine
-
von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834-9.
-
(1997)
Thromb Haemost
, vol.78
, pp. 834-839
-
-
von dem Borne, P.A.1
Mosnier, L.O.2
Tans, G.3
Meijers, J.C.4
Bouma, B.N.5
-
31
-
-
80055107829
-
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma
-
Brummel-Ziedins KE, Whelihan MF, Rivard GE, Butenas S. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma. J Thromb Haemost 2011; 9: 2262-7.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 2262-2267
-
-
Brummel-Ziedins, K.E.1
Whelihan, M.F.2
Rivard, G.E.3
Butenas, S.4
-
32
-
-
33750058557
-
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management
-
Butenas S, Orfeo T, Kalafatis M, Mann KG. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management. J Thromb Haemost 2006; 4: 2411-6.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 2411-2416
-
-
Butenas, S.1
Orfeo, T.2
Kalafatis, M.3
Mann, K.G.4
-
33
-
-
33747501427
-
Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders
-
De Nanteuil G, Gloanec P, Beguin S, Giesen PL, Hemker HC, Mennecier P, Rupin A, Verbeuren TJ. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders. J Med Chem 2006; 49: 5047-50.
-
(2006)
J Med Chem
, vol.49
, pp. 5047-5050
-
-
De Nanteuil, G.1
Gloanec, P.2
Beguin, S.3
Giesen, P.L.4
Hemker, H.C.5
Mennecier, P.6
Rupin, A.7
Verbeuren, T.J.8
|